Broad-Spectrum Antiviral Compounds Targeting Viral Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs are limited in their ability to effectively prevent and treat viral infections, particularly chronic and debilitating viruses like HIV and hepatitis C, as they often cause toxicity and are ineffective against latent viruses, and new viral threats such as Ebola and Venezuelan Equine Encephalitis pose significant public health risks.
Innovation Solution
Development of novel compounds with broad-spectrum antiviral properties that can target multiple viral families, including bunyaviruses, flaviviruses, and togaviruses, by administering therapeutically effective amounts of specific pharmaceutical compounds to treat viral diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral drugs inhibit viral replication through transcription inhibition, then viral replication is suppressed, but toxicity increases and latent viruses remain untreated
Solution Approach 1:
The patent introduces a novel compound structure (Formula I) as an intermediary agent that disrupts the virus-host interaction. Instead of directly inhibiting viral transcription like conventional drugs, these compounds act as mediators that interfere with viral entry or early replication processes, thereby reducing the need for continuous high-dose transcription inhibition and associated toxicity
Solution Approach 2:
The patent employs parameter changes by modifying chemical structures (various R1-R6 substituents in Formula I) to optimize the balance between antiviral efficacy and host toxicity. By systematically varying molecular parameters such as lipophilicity, hydrogen bonding capacity, and steric properties, the compounds achieve enhanced selectivity for viral targets while minimizing off-target effects on host cells
2Reliability
If antiviral drugs target specific viral proteins, then replication is inhibited, but viral resistance develops through mutations
Solution Approach 1:
The patent applies universality by designing compounds with broad-spectrum activity against multiple viral families. The core structure (Formula I) with various substituent patterns demonstrates efficacy against diverse viruses including but not limited to specific families, making it difficult for viruses to develop resistance through single-point mutations. This multi-functional approach allows the same compound to target different viral entry or replication mechanisms across virus types
3Reliability
If antiviral treatment is continued indefinitely, then latent viruses are suppressed, but patient quality of life deteriorates
Solution Approach 1:
The patent applies preliminary action by designing compounds that address viral threats before they become established or latent. The molecular structures (Formula I) are configured to interfere with early viral processes such as entry or initial replication, preventing the establishment of persistent infections. This proactive approach may reduce or eliminate the need for long-term suppressive therapy, thereby improving patient compliance and quality of life
Data Source
AI summary
Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.